According to FutureWise analysis, the Pharmacogenomics market in 2026 is US$21.55 billion, and is expected to reach US$ 62.86 billion by 2036 at a CAGR of 11.30%.
Growth is driven by increasing adoption of precision medicine and gene-guided drug prescribing. Rising demand for personalised therapies is expanding pharmacogenomic testing across clinical settings. Pharmaceutical companies are increasingly integrating PGx data into drug development and clinical trials. Advancements in next-generation sequencing and molecular diagnostics are supporting market expansion. Hospitals and diagnostic laboratories are adopting pharmacogenomics to improve treatment efficacy and reduce adverse drug reactions. Expanding applications in oncology, cardiology, and psychiatry continue to strengthen long-term market growth.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Pharmacogenomics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Pharmacogenomics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.